Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: A postmarketing surveillance study

Journal of Human Hypertension

Volumn 18, Issue 9, 2004, Pages 669-675

  Sharma, A M ^a   Wagner, T ^b   Marsalek, P ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Hypertension; Metabolic syndrome; Moxonidine; Obesity

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MOXONIDINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLELITHIASIS; CLINICAL OBSERVATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; GERMANY; HEADACHE; HUMAN; HYPERVENTILATION; LEG FRACTURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL DOCUMENTATION; MEDICAL PRACTICE; MEDICAL SOCIETY; METABOLIC SYNDROME X; NAUSEA; OBESITY; POSTMARKETING SURVEILLANCE; STROKE; VERTIGO; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL, HDL; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PREVALENCE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 4544367034     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001676     Document Type: Article

References (33)

1. Camus JP. Goutte, diabete, hyperlipemie. Un trisyndrome metabolique. Revue du Rhumatisme 1966; 33: 10-14.
2. Jahnke K et al. Hormonal and metabolic aspects of obesity in humans. In: Östmann J (ed.). Diabetes. Proceedings of the 6th Congress of the International Diabetes Federation. Excerpta Medica Foundation: Amsterdam, 1969, pp. 533-539.
3. Mehnert H, Kuhlmann H. Hypertonie und Diabetes mellitus. Dtsch Med J 1968; 19: 567-571.
4. Reaven GM. Banting lecture 1998. Role of insulin resistance in human diseases. Diabetes 1969; 37: 1595-1607.
5. Alberti KG, Zimmet PC. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
6. Burt VL et al. Prevalence of hypertension in the US adult population. Results from the third national health and nutrition examination survey, 1988-1991. Hypertension 1995; 25: 305-313.
7. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 304-310.
8. Lakka H-M et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
9. Laaksonen DE et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 158: 1070-1077.
10. Borch-Johnson K et al. Blood pressure after 40 years of insulin-dependent diabetes. Nephron 1995; 4: 11-12.
11. Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
12. UKPDS group. Tight blood pressure control an risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS38. BMJ 1998; 317: 703-713.
13. WHO/ISH. Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
14. Hochdruckliga. Leitlinie für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. Dtsch Med Wochenschr 2001; 126 (Suppl. 4): 201-238.
15. ALLHAT officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997.
16. Ehrnsberger P. Pharmacology of moxonidine: An I1-imidazoline receptor antagonist. J Cardiovasc Pharmacol 2000; 35: S27-S41.
17. Prichard BN et al. A double blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20: S45-S49.
18. Schäfers R et al. Wirksamkeit und Verträglichkeit des neuen zentralwirsamen Antihypertensivums Moxonidin im Vergleich zu Enalapril. Nieren und Hochdruckkrankheiten 1994; 5: S221-S224.
19. Waters J et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertenion - results of the TOPIC study. J Clin Basic Cardiol 1999; 2: 219.
20. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: A comparison. J Cardiovasc Pharmacol 1992; 20: S42-44.
21. Chrisp P, Faulds D. Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. Drugs 1992; 44: 993-1012.
22. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999; 17 (Suppl. 3): 29-35.
23. Kaan EC et al. Effects of agmantine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risc Factors 1995; 5 (Suppl. 1): 19-27.
24. Marsalek P, Helsberg K, Motz W. Hypertoniebehandlung mit Moxonidin: Anwendungsbeobachtung dokumentiert Wirkung, Verträ glichkeit und ärztliches Therapieverhalten. Perfusion 2002; 15: 191-200.
25. Prichard BN et al. Moxonidine: a new antiadrenergic antihypertensive agent. J Hypertens 1999; 17 (Suppl. 3): S41-S54.
26. Prichard BN et al. The use of moxonidine in the treatment of hypertension. J Hypertens 1999; 15 (Suppl. 11): 1366.
27. Vonend O et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-1717.
28. Fagard RH et al. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297-1302.
29. National Institute of Health. Diagnosis and Management of Hypertension - 1987. A Nationwide Survey of Physicians' Knowledge, Attitude, and Reported Behavior. NIH Publication: Bethesda, MD, 1989, pp. 89-2968.
30. Hagemeister J et al. Hypertension guidelines and their limitations - the impact of physicians compliance as evaluated by guidelines awareness. J Hypertens 2001; 19: 2079-2086.
31. Aparina TV et al. ACE-dependent and sympathetic components of blood pressure regulation in patients with essential hypertension. Vopr Med Khim 2001; 47: 411-418.
32. Lithell HO. Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. J Hypertens 1997; 15: S39-S42.
33. Sanjuliani AF et al. Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients. Am J Hypertens 2000; 13: 144A.